Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells

RC Ferry, CD Unsworth and PB Molinoff

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104-6084.

Studies of the regulation of 5-hydroxytryptamine (5-HT2) receptors in vivo have generated anomalous and sometimes contradictory results. In particular, administration of antagonists unexpectedly results in a reduction in the density of 5-HT2 receptors. P11 cells, which express a high density of 5-HT2 receptors coupled to phosphoinositide hydrolysis, were used to investigate the regulation of receptors in vitro by agonists, partial agonists, and antagonists. (+/-)-2,5-Dimethoxy-4- iodophenylisopropylamine (DOI) and (+)-lysergic acid diethylamide (LSD) caused marked reductions in the density of 5-HT2 receptors as has been observed in vivo. Down-regulation was prevented by coincubation with ketanserin. The decrease in the density of 5-HT2 receptors after exposure to 5-HT, LSD, or DOI was time dependent and was not a consequence of residual drug in binding assays or irreversibly bound drug. The ability of 5-HT, DOI, and LSD to down-regulate 5-HT2 receptors was not proportional to the ability of these compounds to stimulate phosphoinositide hydrolysis. Ketanserin and mianserin, antagonists which cause paradoxical decreases in the density of 5-HT2 receptors in vivo, did not alter the density of 5-HT2 receptors on P11 cells, even after prolonged incubation with drug. Results of the current studies, which demonstrate agonist- but not antagonist-induced down-regulation of 5-HT2 receptors, lead to the conclusion that the ability of ketanserin and mianserin to down-regulate receptors in vivo is the result of indirect actions of these drugs and is unlikely to be a direct consequence of receptor occupancy by antagonists.

Volume 43, Issue 5, pp. 726-733, 05/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. C. Quinn, N. N. Johnson-Farley, J. Yoon, and D. S. Cowen Activation of Extracellular-Regulated Kinase by 5-Hydroxytryptamine2A Receptors in PC12 Cells is Protein Kinase C-Independent and Requires Calmodulin and Tyrosine Kinases J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 746 - 752. [Abstract] [Full Text] [PDF]

				N. R. S. Hanley and J. G. Hensler Mechanisms of Ligand-Induced Desensitization of the 5-Hydroxytryptamine2A Receptor J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 468 - 477. [Abstract] [Full Text] [PDF]

				N. Hukovic, M. Rocheville, U. Kumar, R. Sasi, S. Khare, and Y. C. Patel Agonist-dependent Up-regulation of Human Somatostatin Receptor Type 1 Requires Molecular Signals in the Cytoplasmic C-tail J. Biol. Chem., August 27, 1999; 274(35): 24550 - 24558. [Abstract] [Full Text] [PDF]

				E. A. Thomas, M. J. Carson, M. J. Neal, and J. G. Sutcliffe Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide PNAS, December 9, 1997; 94(25): 14115 - 14119. [Abstract] [Full Text] [PDF]

				D. S. Cowen, P. B. Molinoff, and D. R. Manning 5-Hydroxytryptamine1A Receptor-Mediated Increases in Receptor Expression and Activation of Nuclear Factor-kappa B in Transfected Chinese Hamster Ovary Cells Mol. Pharmacol., August 1, 1997; 52(2): 221 - 226. [Abstract] [Full Text]